ReviewCancer treatment and research2025
Novel Immune Modulatory Agents in the Treatment of Non-small Cell Lung Cancer.
Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) makes up the large majority of lung cancer diagnoses. After the discovery of immune modulators or immunotherapy, treatments that could utilize the patient's own immune system to target malignant cells, the landscape of lung cancer treatment, NSCLC in particular, has greatly evolved with vast improvements in outcomes and survival. Currently, immune checkpoint inhibitors (ICI) have had the greatest impact on the current treatment of non-driver mutated non-small cell lung cancer. Unfortunately, resistance to treatment whether primary or secondary, remains a concern. To overcome resistance, investigators have sought combination immune modulator treatments and have even identified novel agents to utilize, including adoptive cellular therapies, antibody-drug conjugates, and vaccines. Some of these agents have been more successful than others with combination strategies currently leading the way but there are some limitations. Other agents are early in development and will need to await further data before determining the impact on lung cancer treatment. Immunotherapy or immune modulatory agents remain an essential aspect of NSCLC treatment and continue to be the subject of novel research and development.
Indexed as
Identifiers
40847233What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.